Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02139072 · ClinicalTrials.gov registry record
CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients
A clinical trial of Antiphospholipid Antibody Syndrome, sponsored by University of Florida.
- Completed
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT02139072: Completed study of Antiphospholipid Antibody Syndrome, sponsored by University of Florida.
NCT02139072 is a study of Antiphospholipid Antibody Syndrome that has completed, run by University of Florida. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02139072, a study of Antiphospholipid Antibody Syndrome, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if the CoaguChek XS is accurate in measuring International Normalized Ratio (INR) in patients with Antiphospholipid Antibody Syndrome (APL) receiving warfarin therapy.
Primary Outcome
Compare INR obtained by CoaguChek XS to INR obtained from venous lab draw. Difference of +/- 0.5 considered significant
Conditions Studied
Interventions
- DEVICE CoaguChek XS
- PROCEDURE Standard Lab Draw
Study Locations (1)
Florida
- UF and Shands Health - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-01 |
What the finished NCT02139072 record still lists
NCT02139072 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 1 condition, with Antiphospholipid Antibody Syndrome appearing as the primary indexed condition, and to 2 interventions - of which CoaguChek XS is the first listed.
NCT02139072 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02139072 about?
NCT02139072 is a clinical study titled "CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients". The purpose of this study is to see if the CoaguChek XS is accurate in measuring International Normalized Ratio (INR) in patients with Antiphospholipid Antibody Syndrome (APL) receiving warfarin therapy.
What is the current status of trial NCT02139072?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2015-03. Estimated completion is 2016-01.
What conditions does trial NCT02139072 study?
This clinical trial studies the following conditions: Antiphospholipid Antibody Syndrome.
What interventions are being tested in trial NCT02139072?
The interventions under investigation include: CoaguChek XS (DEVICE), Standard Lab Draw (PROCEDURE).
Who is sponsoring clinical trial NCT02139072?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02139072 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Antiphospholipid Antibody Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia